The Drug Enforcement Administration proposes to transfer glutethimide from Schedule III to Schedule II of the Controlled Substances Act in a July 26 Federal Register notice. The action is based on evidence of abuse and diversion of the drug and on the recommendation of the Assistant Secretary for Health. Comments must be submitted by Sept. 24. FDA's Drug Abuse Advisory Committee recommended that the hypnotic sedative be moved to Schedule II ("The Pink Sheet" June 11, T&G-4). A number of generic firms manufacture the drug.
You may also be interested in...
IBA’s name change refines its identity as the representative of the independent and entrepreneurial beauty industry, according to the trade organization’s announcement. The group’s FDA Cosmetics Regulation Workshop, held annually since 1983 in cooperation with the FDA, will be virtual in 2020.
Justice Ginsburg wrote two decisions in pharmaceutical related-cases over the past decade, joined the majority in opinions on the scope of patents, and dissented in decisions giving protection to generic manufacturers and speech of pharmaceutical companies. Her death could impact the outcome of cases challenging the Affordable Care Act.
DuPont says it and P&G “have conducted extensive research on human commensals bacteria to help address metabolic health issues in humans.” The partnership "will help us further advance our probiotic innovation via a next generation solution that will prove beneficial to the health and well-being of consumers around the world,” says Paul Gama, P&G personal health care president.